Cannon Martin J, O'Brien Timothy J
University of Arkansas for Medical Sciences, Department of Microbiology and Immunology, 4301 West Markham, Little Rock, AR 72205, USA.
Expert Opin Biol Ther. 2009 Jun;9(6):677-88. doi: 10.1517/14712590902932897.
Ovarian cancer is frequently diagnosed at an advanced stage, and although initially responsive to surgery and chemotherapy, has a high rate of recurrence and mortality. Cellular immunotherapy may offer the prospect of treatment to prevent or delay recurrent metastatic disease.
To provide an overview of current innovations in cellular immunotherapy for ovarian cancer, with an emphasis on dendritic cell vaccination and adoptive T-cell immunotherapy.
Three key areas are explored in this review: first, an appraisal of the current state of the art of cellular immunotherapy for treatment of ovarian cancer; second, a discussion of the immunological defenses erected by ovarian cancer to prevent immunological attack, with an emphasis on the role of tumor-associated regulatory T cells; and third, an exploration of innovative techniques that may enhance the ability of cellular immunotherapy to overcome ovarian tumor-associated immune suppression.
RESULTS/CONCLUSION: Ovarian cancer is recognized as a paradigm for tumor-associated immune suppression. Innovative approaches for antagonism of tumor-associated regulatory T-cell infiltration and redirection of self antigen-driven regulatory T-cell activation may provide the key to development of future strategies for cellular immunotherapy against ovarian cancer.
卵巢癌常常在晚期才被诊断出来，尽管其最初对手术和化疗有反应，但复发率和死亡率很高。细胞免疫疗法可能为预防或延缓复发性转移性疾病提供治疗前景。
概述卵巢癌细胞免疫疗法的当前创新，重点是树突状细胞疫苗接种和过继性T细胞免疫疗法。
本综述探讨了三个关键领域：第一，评估卵巢癌细胞免疫疗法的当前技术水平；第二，讨论卵巢癌建立的免疫防御以防止免疫攻击，重点是肿瘤相关调节性T细胞的作用；第三，探索可能增强细胞免疫疗法克服卵巢肿瘤相关免疫抑制能力的创新技术。
结果/结论：卵巢癌被认为是肿瘤相关免疫抑制的范例。对抗肿瘤相关调节性T细胞浸润和重新引导自身抗原驱动的调节性T细胞活化的创新方法可能是未来卵巢癌细胞免疫治疗策略发展的关键。
